|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2000-4-27
|
|
pubmed:abstractText |
The authors tested a biotherapy regimen involving recombinant interferon-alpha-2a (rIFN-alpha-2a) and recombinant human interleukin-2 (rhIL-2), given in a "decrescendo" schedule over 5 days, for its activity and toxicity in 21 patients who previously had received chemotherapy for advanced melanoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2000 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
88
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1703-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10738230-Adult,
pubmed-meshheading:10738230-Aged,
pubmed-meshheading:10738230-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10738230-Blood Cell Count,
pubmed-meshheading:10738230-Cytokines,
pubmed-meshheading:10738230-Female,
pubmed-meshheading:10738230-Humans,
pubmed-meshheading:10738230-Interferon-alpha,
pubmed-meshheading:10738230-Interleukin-2,
pubmed-meshheading:10738230-Male,
pubmed-meshheading:10738230-Melanoma,
pubmed-meshheading:10738230-Middle Aged,
pubmed-meshheading:10738230-Neoplasm Metastasis,
pubmed-meshheading:10738230-Recombinant Proteins,
pubmed-meshheading:10738230-Salvage Therapy
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy.
|
|
pubmed:affiliation |
Department of Melanoma/Sarcoma, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
